BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals (BCRX) announced its participation in several key investor conferences. The company will present at the Bank of America Securities 2022 Healthcare Conference on May 10 at 11:00 a.m. ET in Las Vegas, and at the RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 p.m. ET in New York. Additionally, a pre-recorded fireside chat at the H.C. Wainwright Global Investment Conference will be accessible starting May 24 at 7:00 a.m. ET. Live webcasts will be available on BioCryst's investor relations website.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
- The Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at 11:00 a.m. ET.
- The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 18, 2022 at 1:35 p.m. ET.
- The H.C. Wainwright Global Investment Conference – pre-recorded fireside chat available beginning Tuesday, May 24, 2022 at 7:00 a.m. ET.
Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
FAQ
When will BioCryst Pharmaceuticals present at the Bank of America Securities 2022 Healthcare Conference?
What date will BioCryst Pharmaceuticals present at the RBC Capital Markets Global Healthcare Conference?
When will the H.C. Wainwright Global Investment Conference fireside chat be available?
How can I access the live audio webcasts of BioCryst Pharmaceuticals' presentations?
